Edition:
India

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

95.99USD
2:29am IST
Change (% chg)

$0.11 (+0.11%)
Prev Close
$95.88
Open
$96.75
Day's High
$97.41
Day's Low
$95.78
Volume
96,304
Avg. Vol
156,379
52-wk High
$108.27
52-wk Low
$44.68

Chart for

About

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for... (more)

Overall

Beta: --
Market Cap(Mil.): $3,310.99
Shares Outstanding(Mil.): 31.93
Dividend: --
Yield (%): --

Financials

BRIEF-Avexis posts Q3 loss per share $1.52

* Avexis reports third quarter 2017 financial and operating results

10 Nov 2017

BRIEF-Avexis Inc CFO Thomas Dee resigns

* Avexis Inc - ‍on October 14 Thomas J. Dee resigned as senior vice president, chief financial officer - SEC filing

20 Oct 2017

BRIEF-AveXis to report top-line data from phase 1 clinical trial of AVXS-101

* AveXis to report top-line data from the Phase 1 clinical trial of AVXS-101 in SMA Type 1 at the International Annual Congress Of The World Muscle Society

03 Oct 2017

BRIEF-Avexis to initiate pivotal trial of AVXS-101 in SMA type 1

* Avexis announces plan to initiate pivotal trial of AVXS-101 in SMA type 1 using product from new GMP commercial process

29 Sep 2017

BRIEF-AveXis reports Q2 loss per share $2.07

* AveXis reports second quarter 2017 financial and operating results

11 Aug 2017

BRIEF-Avexis announces alignment with FDA on GMP commercial manufacturing process for AVXS-101

* Avexis announces alignment with FDA on GMP commercial manufacturing process for AVXS-101

15 Jun 2017

BRIEF-Avexis and Regenxbio announce new exclusive worldwide licenses

* Avexis and Regenxbio announce new exclusive worldwide licenses for the treatment of two rare neurological monogenic disorders using NAV AAV9 vector

08 Jun 2017

Earnings vs. Estimates